TLSA Tiziana Life Sciences Ltd
$0.92▲ +4.97%
Healthcare
Other
Volume 157.9K
Avg Volume (10D) 377.1K
Key Metrics & Fundamentals
Market Cap
$116.48M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.76 - 1.96
% vs 50 MA
-14.33%
% vs 200 MA
-28.62%
RSI-14
34.4
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.38
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
GlobeNewswire · Oct 21, 2026 7:00 AM ET
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires · Oct 16, 2026 9:11 AM ET
Sector Update: Healthcare
MT Newswires · Oct 16, 2026 8:58 AM ET
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab
Proactive · Oct 16, 2026 8:38 AM ET
Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Intranasal Foralumab in Alzheimer's Disease
MT Newswires · Oct 16, 2026 7:25 AM ET
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
GlobeNewswire · Oct 16, 2026 7:00 AM ET
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Proactive · Sep 30, 2026 8:54 AM ET
MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq
Proactive · Sep 30, 2026 7:14 AM ET
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
GlobeNewswire · Sep 30, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.